TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24831039

Group type: EXPERIMENTAL
Intervention: Web-based communication for support
Number of subjects: 30
Study: 23835185

Group type: EXPERIMENTAL
Intervention: Individualised physiotherapy‐directed occupational health programme (six 30‐minute sessions over 5 months)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group with pseudo-intervention of one oral education session
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Individualised physiotherapy‐directed occupational health programme
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group with pseudo-intervention
Number of subjects: 69
Study: 23054196

Group type: EXPERIMENTAL
Intervention: VHS: single implementation intention
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: VHS: multiple implementation intentions
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Self-generated implementation intention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 69
Study: 20104986

Group type: EXPERIMENTAL
Intervention: High intake of vegetables
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fruit consumption
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Consumption of foods fried in vegetable oil
Number of subjects: 114
Study: 17875340

Group type: EXPERIMENTAL
Intervention: Epoetin beta 150 IU/kg three times weekly until 4 weeks after last chemotherapy cycle
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 102
Study: 15986591

Group type: EXPERIMENTAL
Intervention: CMF as preoperative second-line chemotherapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Paclitaxel or docetaxel as second-line treatment
Number of subjects: 13
Study: 12454562

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rivastigmine (9 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combined effects of donepezil and rivastigmine
Number of subjects: 11
Study: 10554542

Group type: EXPERIMENTAL
Intervention: Selenium treatment for 19 days in addition to a complete in-patient rehabilitation cure based on a behavioural approach
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (41 patients)
Number of subjects: 53
Study: 8974615

Group type: EXPERIMENTAL
Intervention: Short-acting GnRH agonist (effective for 24 hours)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Long-acting GnRH analog
Number of subjects: 160
Study: 1718252

Group type: EXPERIMENTAL
Intervention: Laser treatment for classic CNV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser treatment for subfoveal recurrent CNV
Number of subjects: 0
Study: 6352267

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg oral)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg three times daily)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30703644

Group type: EXPERIMENTAL
Intervention: 1-month DAPT group (abbreviated antiplatelet regimen)
Number of subjects: 4300

Group type: COMPARATOR
Intervention: Standard antiplatelet regimen (at least 5 months DAPT)
Number of subjects: 4300
Study: 26990786

Group type: EXPERIMENTAL
Intervention: Group cell phone intervention
Number of subjects: 195
Study: 25650816

Group type: EXPERIMENTAL
Intervention: Ivor‐Lewis esophagectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sweet esophagectomy
Number of subjects: 300
Study: 24337476

Group type: EXPERIMENTAL
Intervention: Stand up comedy training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Discussing comedy videos (active control)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No humour-related intervention (passive control)
Number of subjects: 36
Study: 22855868

Group type: EXPERIMENTAL
Intervention: Barbecue rotation
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Gufoni maneuver
Number of subjects: 170

Group type: COMPARATOR
Intervention: Sham maneuver
Number of subjects: 170
Study: 19947792

Group type: EXPERIMENTAL
Intervention: Fagerström Test for Nicotine Dependence
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Nicotine Dependence Syndrome Scale
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Wisconsin Inventory of Smoking Dependence Motives
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Nicotine dependence measures' scales and items
Number of subjects: 608
Study: 17207304

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 15754485

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 0
Study: 11409115

Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel)
Number of subjects: 628
Study: 9926571

Group type: EXPERIMENTAL
Intervention: Alcohol (100 mg/100 ml dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7865642

Group type: EXPERIMENTAL
Intervention: Smooth muscle relaxants (myorelaxants)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2838221

Group type: EXPERIMENTAL
Intervention: Uniroid ointment
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Proctosedyl ointment
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Uniroid suppository
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Proctosedyl suppository
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both ointment and suppository formulations
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: All four preparations
Number of subjects: 89
Study: 31995570

Group type: EXPERIMENTAL
Intervention: Daily lipid‐based micronutrient supplement commencing ≥3 months prior to conception (Arm 1)
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Daily lipid‐based micronutrient supplement in the 1st trimester (Arm 2)
Number of subjects: 972

Group type: COMPARATOR
Intervention: Control group (no supplement, Arm 3)
Number of subjects: 972
Study: 29446523

Group type: EXPERIMENTAL
Intervention: Triple therapy with dapagliflozin 10 mg/d plus saxagliptin 5 mg/d plus metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual therapy with dapagliflozin or saxagliptin plus metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential add-on therapy with dapagliflozin 10 mg/d or saxagliptin 5 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant add-on therapy with dapagliflozin 10 mg/d plus saxagliptin 5 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All analysis groups
Number of subjects: 0
Study: 28449699

Group type: EXPERIMENTAL
Intervention: Full-length shoe-stiffening insert(s) plus rehabilitation therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham shoe insert(s) plus rehabilitation therapy
Number of subjects: 90
Study: 26134993

Group type: EXPERIMENTAL
Intervention: Heparin and protamine dosing with Hepcon HMS Plus device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard weight and activated clotting time (ACT) based dosing
Number of subjects: 60
Study: 22834636

Group type: EXPERIMENTAL
Intervention: 15(R/S)-methyl-lipoxin A(4) cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (Eloson)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21054484

Group type: EXPERIMENTAL
Intervention: Injection of 0.5 mL of hypertonic saline
Number of subjects: 11

Group type: COMPARATOR
Intervention: Injection of 0.5 mL of isotonic saline
Number of subjects: 11
Study: 18298709

Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam 1 mg
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 16376489

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 (D1, D22, D43); 5FU, continuous infusion (D1‐‐>D5), 750 mg/m2/day cycle 1; 430 mg/m2/day cycles 2 and 3
Number of subjects: 163

Group type: COMPARATOR
Intervention: Radiotherapy alone (arm A)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cisplatin/5-FU chemotherapy (arm B)
Number of subjects: 163
Study: 12821730

Group type: EXPERIMENTAL
Intervention: Insulin (1.0 mU x kg(‐1) x min(‐1)) plus dextrose to maintain euglycemia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study: 10587317

Group type: EXPERIMENTAL
Intervention: Danish vaccine (normal dose, 0.05 ml) given to neonates at birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danish vaccine (half the normal dose) given at birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IRP vaccine given at birth at normal infant dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danish vaccine (normal infant dose) given at 3 months of age
Number of subjects: 0
Study: 8561341

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (Control)
Number of subjects: 20
Study: 1670113

Group type: EXPERIMENTAL
Intervention: L-PAM (melphalan) or L-PAM plus fluorouracil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group from trial B-05
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent treated subgroups from four studies
Number of subjects: 0
Study: 6120059

Group type: EXPERIMENTAL
Intervention: 7.5 mg CZP nightly with no antacid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CZP nightly for 30 ml Maalox
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CZP nightly with Maalox with an additional 30 ml Maalox three times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no antacid)
Number of subjects: 10
Study: 30224529

Group type: EXPERIMENTAL
Intervention: Chinfloxacin 400 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chinfloxacin 600 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chinfloxacin (single and multiple doses)
Number of subjects: 100
Study: 27229713

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Azacitidine + Epoetin-β
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: SF3B1 mutation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Detection of epigenetic mutation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Abnormal SNP array profile
Number of subjects: 98
Study: 26274517

Group type: EXPERIMENTAL
Intervention: Toric, aspheric Bi‐Flex T toric IOLs (Medicontur Medical Engineering Ltd., Inc.)
Number of subjects: 20
Study: 24119130

Group type: EXPERIMENTAL
Intervention: Comprehensive care pathway at University Medical Center Groningen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual in two other nonacademic hospitals
Number of subjects: 0
Study: 21862748

Group type: EXPERIMENTAL
Intervention: Anti-IL-12/23 therapies (ustekinumab and briakinumab)
Number of subjects: 10183

Group type: EXPERIMENTAL
Intervention: Anti-TNF-α agents (adalimumab, etanercept, infliximab)
Number of subjects: 10183

Group type: COMPARATOR
Intervention: Placebo (for anti-IL-12/23 therapies)
Number of subjects: 10183

Group type: COMPARATOR
Intervention: Placebo (for anti-TNF-α agents)
Number of subjects: 10183
Study: 19065858

Group type: EXPERIMENTAL
Intervention: Motion condition (apparent motion induced by a preceding neutral face image followed by an emotional face image)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repetition condition (same emotional face image presented twice)
Number of subjects: 0
Study: 16600929

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Folic acid + iron
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Folic acid + iron + zinc
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (folic acid, iron, zinc, and 11 other nutrients) + vitamin A
Number of subjects: 740

Group type: COMPARATOR
Intervention: Vitamin A alone
Number of subjects: 740
Study: 14651700

Group type: EXPERIMENTAL
Intervention: Listening to music for 20 minutes daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sitting quietly for 20 minutes daily (Control)
Number of subjects: 66
Study: 10981543

Group type: EXPERIMENTAL
Intervention: Combination diet rich in fruits, vegetables, low-fat dairy, whole grains, fish, poultry, and nuts; reduced in fats, red meats, sweets, and sugar-containing beverages for 8 weeks
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fruits-and-vegetables diet for 8 weeks
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control diet for 8 weeks
Number of subjects: 133
Study: 9191677

Group type: EXPERIMENTAL
Intervention: Immune-enhancing diet (XD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 43
Study: 9601228

Group type: EXPERIMENTAL
Intervention: Myofunctional therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Myofunctional therapy and orthodontic appliances (e.g., activators)
Number of subjects: 28
Study: 3515464

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-CO2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-HCl
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both bupivacaine-CO2 and bupivacaine-HCl
Number of subjects: 16
Study: 30786846

Group type: COMPARATOR
Intervention: CF-ATL
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CF-OTS
Number of subjects: 3

Group type: COMPARATOR
Intervention: NPAC
Number of subjects: 3
Study: 29330256

Group type: EXPERIMENTAL
Intervention: Osteoprotegerin levels
Number of subjects: 5135

Group type: EXPERIMENTAL
Intervention: Osteoprotegerin concentrations
Number of subjects: 5135
Study: 27595590

Group type: EXPERIMENTAL
Intervention: Perampanel (8‐12mg/day)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 24875194

Group type: EXPERIMENTAL
Intervention: Losartan 0.1 mg/kg per day
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Losartan 0.3 mg/kg per day
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Losartan 0.7 mg/kg per day
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Losartan (up to 1.4 mg/kg per day)
Number of subjects: 101
Study: 21810842

Group type: EXPERIMENTAL
Intervention: Aspirin taken in the evening for 1 month
Number of subjects: 75

Group type: COMPARATOR
Intervention: Aspirin taken in the morning for 1 month
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Aspirin taken in the evening
Number of subjects: 75

Group type: COMPARATOR
Intervention: Aspirin taken in the morning
Number of subjects: 75
Study: 19952833

Group type: EXPERIMENTAL
Intervention: Yoga therapy (YG)
Number of subjects: 40
Study: 18082451

Group type: EXPERIMENTAL
Intervention: Temozolomide plus radiotherapy
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Temozolomide plus radiotherapy (with MGMT assessment)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 573
Study: 16841660

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 14658994

Group type: EXPERIMENTAL
Intervention: Self-efficacy for speech
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speech self-efficacy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluent speakers (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adolescents who stutter
Number of subjects: 0
Study: 10720532

Group type: EXPERIMENTAL
Intervention: OspA vaccine recipients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OspA vaccine recipients with Lyme disease
Number of subjects: 0
Study: 8787872

Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg
Number of subjects: 12
Study: 1465060

Group type: EXPERIMENTAL
Intervention: Protein-restricted diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal protein intake
Number of subjects: 0
Study: 3885456

Group type: EXPERIMENTAL
Intervention: 600 IU vitamin E (n = 37)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (n = 36)
Number of subjects: 73
Study: 31012865

Group type: EXPERIMENTAL
Intervention: High confidence in prior attitudes
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: High source credibility (+1 SD) with low confidence (-1 SD)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Tag popularity
Number of subjects: 520
Study: 30223226

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus goserelin (F + G)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Anastrozole plus goserelin (A + G)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Goserelin (G) alone
Number of subjects: 138
Study: 27565964

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 50
Study: 24222323

Group type: EXPERIMENTAL
Intervention: Fast-track protocol
Number of subjects: 0
Study: 21364931

Group type: EXPERIMENTAL
Intervention: Monetary trust game
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical effort trust game
Number of subjects: 0
Study: 16221299

Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment (PST) provided by nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 12099989

Group type: EXPERIMENTAL
Intervention: Neoral oral solution diluted in apple juice
Number of subjects: 34

Group type: COMPARATOR
Intervention: Neoral oral solution diluted in tap water
Number of subjects: 34
Study: 9776153

Group type: EXPERIMENTAL
Intervention: Intraoperative extraperitoneal instillation of bupivacaine
Number of subjects: 56
Study: 8071496

Group type: EXPERIMENTAL
Intervention: Moderate diet (1.3 g protein/kg/day, 16-20 mg phosphorus/kg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low diet (0.575 g protein/kg/day, 5-10 mg phosphorus/kg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Very low diet with keto or amino acids (0.28 g protein/kg/day, 4-9 mg phosphorus/kg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All diets (Moderate, Low, Very Low)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Diet diaries
Number of subjects: 96
Study: 3378276

Group type: EXPERIMENTAL
Intervention: Combination of gentamicin and methicillin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of gentamicin and cloxacillin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of clindamycin and mezlocillin
Number of subjects: 20
Study: 11595781

Group type: EXPERIMENTAL
Intervention: Weight reduction over 6 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Weight reduction over 12 and 24 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Weight regain after initial weight loss
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 52
Study: 31630580

Group type: EXPERIMENTAL
Intervention: Cervical cerclage and cervical pessary combined
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cervical cerclage alone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cervical pessary alone
Number of subjects: 75
Study: 31113531

Group type: EXPERIMENTAL
Intervention: Surgisis anal fistula plug
Number of subjects: 304

Group type: COMPARATOR
Intervention: Surgeon's preference (e.g. fistulotomy, cutting seton, advancement flap, LIFT procedure)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Surgeon's preference
Number of subjects: 304
Study: 29859160

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study: 27276165

Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Number of subjects: 56

Group type: COMPARATOR
Intervention: Naproxen (250mg TID for 10 days) and physical therapy
Number of subjects: 56
Study: 25386717

Group type: EXPERIMENTAL
Intervention: DNR status (Do Not Resuscitate)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: DNR status (Do Not Resuscitate) without withdrawal of life support
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Admission severity of illness measured by APACHE III score
Number of subjects: 809
Study: 22129488

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 2024

Group type: EXPERIMENTAL
Intervention: Fibrinolysis with rescue PCI
Number of subjects: 2024

Group type: EXPERIMENTAL
Intervention: Fibrinolysis with urgent/elective PCI
Number of subjects: 2024

Group type: EXPERIMENTAL
Intervention: Fibrinolysis without PCI
Number of subjects: 2024

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 2024

Group type: COMPARATOR
Intervention: No PCI during hospitalization
Number of subjects: 2024
Study: 19829136

Group type: EXPERIMENTAL
Intervention: Polyzene-F coated CATANIA stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 0
Study: 17879533

Group type: EXPERIMENTAL
Intervention: Radiotherapy and additional administering of arsenic trioxide (ATO)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional radiotherapy alone
Number of subjects: 74
Study: 15898434

Group type: EXPERIMENTAL
Intervention: Erythromycin stinoprate capsules 250 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Erythromycin stinoprate capsules 500 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Erythromycin stinoprate capsules 750 mg
Number of subjects: 30
Study: 12480357

Group type: EXPERIMENTAL
Intervention: Fibrinogen/LDL apheresis
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard treatment (250 mg prednisolone reduced by 25 mg per day, 500 mL 6% hydroxyethyl starch, 400 mg pentoxifylline per day)
Number of subjects: 201
Study: 9659643

Group type: EXPERIMENTAL
Intervention: rHuEPO (300 U/kg per dose, twice a week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7858363

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg in 3 ml saline) administered before the onset of pain (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Epidural saline (3 ml) administered before the onset of pain (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg in 3 ml saline) administered after the onset of pain (Group B)
Number of subjects: 90